Abstract
Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and delivery strategies to achieve positive clinical results. The unique immunoglobulin (Ig) idiotype on the surface of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a cancer vaccine. It has been theorized that effective cancer vaccines can be developed using the minimum essential subset of T cell and B cell epitopes that comprise the ‘immunome’, the universe of neoplasm-derived peptides that interface with B and T cells of the host immune system. Idiotypic antigenic determinants of a B-cell lymphoma lie within the hypervariable regions and mainly within the complementarity-determining regions (CDR)s 3. Thus, the CDR3s are considered a “hot spot” of particular interest for construction of subunit vaccines. DNA vaccines, whose safety and tolerability are substantiated in completed and ongoing clinical trials, have emerged as a novel lymphoma vaccine formulation for antigen-specific immunotherapy. The molecular precision tools offered by gene-based vaccines allow to explore the use of CDR3 sequence as an antilymphoma vaccine.
Keywords: cancer vaccines, DNA vaccines, immunotherapy, personalised medicine, preclinical models, targeted cancer therapies, tumor-specific antigens, chemotherapy, Tumor-associated-antigen
Current Gene Therapy
Title: Design and Pre-Clinical Development of Epitope-based DNA Vaccines Against B-Cell Lymphoma
Volume: 11 Issue: 5
Author(s): Sandra Iurescia, Daniela Fioretti, Vito Michele Fazio and Monica Rinaldi
Affiliation:
Keywords: cancer vaccines, DNA vaccines, immunotherapy, personalised medicine, preclinical models, targeted cancer therapies, tumor-specific antigens, chemotherapy, Tumor-associated-antigen
Abstract: Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and delivery strategies to achieve positive clinical results. The unique immunoglobulin (Ig) idiotype on the surface of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a cancer vaccine. It has been theorized that effective cancer vaccines can be developed using the minimum essential subset of T cell and B cell epitopes that comprise the ‘immunome’, the universe of neoplasm-derived peptides that interface with B and T cells of the host immune system. Idiotypic antigenic determinants of a B-cell lymphoma lie within the hypervariable regions and mainly within the complementarity-determining regions (CDR)s 3. Thus, the CDR3s are considered a “hot spot” of particular interest for construction of subunit vaccines. DNA vaccines, whose safety and tolerability are substantiated in completed and ongoing clinical trials, have emerged as a novel lymphoma vaccine formulation for antigen-specific immunotherapy. The molecular precision tools offered by gene-based vaccines allow to explore the use of CDR3 sequence as an antilymphoma vaccine.
Export Options
About this article
Cite this article as:
Iurescia Sandra, Fioretti Daniela, Michele Fazio Vito and Rinaldi Monica, Design and Pre-Clinical Development of Epitope-based DNA Vaccines Against B-Cell Lymphoma, Current Gene Therapy 2011; 11 (5) . https://dx.doi.org/10.2174/156652311797415863
DOI https://dx.doi.org/10.2174/156652311797415863 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry
Current Medical Imaging Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis
Current Chemical Biology Hybrid Viral Vectors for Vaccine and Antibody Production in Plants
Current Pharmaceutical Design Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry Knockdown of Enhancer of Zeste Homolog 2 Affects mRNA Expression of Genes Involved in the Induction of Resistance to Apoptosis in MOLT-4 Cells
Anti-Cancer Agents in Medicinal Chemistry ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology
Current Medicinal Chemistry subject Index To Volume 1
Current Molecular Medicine Luteolin Stimulates Proliferation and Inhibits Late Differentiation of Primary Rat Calvarial Osteoblast Induced by High-dose Dexamethasone via Sema3A /NRP1/Pleixin A1
Current Pharmaceutical Biotechnology Is Resistance Futile?
Current Drug Targets - Infectious Disorders Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition
Current Pharmaceutical Design Long-Term Immunovirogical Effect and Tolerability of a Maraviroc- Containing Regimen in Routine Clinical Practice
Current HIV Research Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science MicroRNAs and Cancer Therapy – From Bystanders to Major Players
Current Medicinal Chemistry Nelarabine- A New Purine Analog in the Treatment of Hematologic Malignancies
Reviews on Recent Clinical Trials Editorial (Thematic Issue: Molecular Aspects of Cancer Resistance to Biological and Non- Biological Drugs and Strategies to Overcome Resistance)
Current Medicinal Chemistry Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy The Relevance of Microdialysis for Clinical Oncology
Current Clinical Pharmacology Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets